Tumor Size Is Not Everything: Advancing Radiomics as a Precision Medicine Biomarker in Oncology Drug Development and Clinical Care. A Report of a Multidisciplinary Workshop Coordinated by the RECIST Working Group-Reference-Cited by-同舟云学术

Tumor Size Is Not Everything: Advancing Radiomics as a Precision Medicine Biomarker in Oncology Drug Development and Clinical Care. A Report of a Multidisciplinary Workshop Coordinated by the RECIST Working Group

Published:2024-06 Issue:8 Volume: Page:
ISSN:2473-4284
Container-title:JCO Precision Oncology
language:en
Short-container-title:JCO Precis Oncol

Author:

Nakajima Erica C.¹,Simpson Amber²^ORCID,Bogaerts Jan³,de Vries Elisabeth G.E.⁴^ORCID,Do Richard⁵^ORCID,Garralda Elena⁶^ORCID,Goldmacher Greg⁷^ORCID,Kinahan Paul E.⁸^ORCID,Lambin Philippe⁹^ORCID,LeStage Barbara¹⁰,Li Qin¹¹^ORCID,Lin Frank¹²^ORCID,Litière Saskia³^ORCID,Perez-Lopez Raquel⁶^ORCID,Petrick Nicholas¹³^ORCID,Schwartz Lawrence⁵,Seymour Lesley¹⁴^ORCID,Shankar Lalitha¹⁵,Laurie Scott A.¹⁶^ORCID

Affiliation:

1. AstraZeneca, Gaithersburg, MD

2. Queen's University, Kingston, ON, Canada

3. EORTC, Brussels, Belgium

4. University Medical Center Groningen, Groningen, the Netherlands

5. Memorial Sloan-Kettering Cancer Center, NY, NY

6. Vall d’Hebron Institute of Oncology, Barcelona, Spain

7. Merck, Rahway, NJ

8. University of Washington, Seattle, WA

9. Maastricht University, Maastricht, the Netherlands

10. Cancer Research Advocate, Wrentham, MA

11. AstraZeneca, Waltham, MA

12. University of Sydney, Sydney, Australia

13. US Food and Drug Administration, Silver Spring, MD

14. Canadian Cancer Trials Group, Queen's University, Kingston, ON, Canada

15. National Cancer Institute, National Institutes of Health, Bethesda, MD

16. The Ottawa Hospital Cancer Centre, University of Ottawa, Ottawa, ON, Canada

Abstract

Radiomics, the science of extracting quantifiable data from routine medical images, is a powerful tool that has many potential applications in oncology. The Response Evaluation Criteria in Solid Tumors Working Group (RWG) held a workshop in May 2022, which brought together various stakeholders to discuss the potential role of radiomics in oncology drug development and clinical trials, particularly with respect to response assessment. This article summarizes the results of that workshop, reviewing radiomics for the practicing oncologist and highlighting the work that needs to be done to move forward the incorporation of radiomics into clinical trials.

Publisher

American Society of Clinical Oncology (ASCO)

Link

https://ascopubs.org/doi/pdfdirect/10.1200/PO.23.00687

Reference35 articles.

1. Reporting results of cancer treatment

2. New Guidelines to Evaluate the Response to Treatment in Solid Tumors

3. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

4. RECIST 1.1 for Response Evaluation Apply Not Only to Chemotherapy-Treated Patients But Also to Targeted Cancer Agents: A Pooled Database Analysis

5. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Testing new anticancer drugs before curative locoregional therapies: MDICT 2024 recommendations;ESMO Open;2024-08

2. Erratum: Tumor Size Is Not Everything: Advancing Radiomics as a Precision Medicine Biomarker in Oncology Drug Development and Clinical Care. A Report of a Multidisciplinary Workshop Coordinated by the RECIST Working Group;JCO Precision Oncology;2024-06

3. Using Radiomics in Cancer Management;JCO Precision Oncology;2024-05